BTK References

Original References:

1. Grassilli E, Pisano F, Cialdella A, et al. A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. Oncogene. 2016;35(33):4368-4378.
2. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies [published correction appears in Mol Cancer. 2019 Apr 3;18(1):79]. Mol Cancer. 2018;17(1):57.
3. Eifert C, Wang X, Kokabee L, et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer. 2013;52(10):961-975.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014 Feb 20;370(8):786]. N Engl J Med. 2013;369(1):32-42.
5. Kozaki R, Vogler M, Walter HS, et al. Responses to the selective Bruton's tyrosine kinase (BTK) inhibitor tirabrutinib (ONO/GS-4059) in diffuse large B-cell lymphoma cell lines. Cancers (Basel). 2018;10(4):127.
6. Campbell R, Chong G, Hawkes EA. Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. J Clin Med. 2018;7(4):62.
7. Wei L, Su YK, Lin CM, et al. Preclinical investigation of ibrutinib, a Bruton’s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 2016;7:69961-69975.
8. Yue C, Niu M, Shan QQ, et al. High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma. J Exp Clin Cancer Res. 2017;36(1):132.
9. Giordano F, Vaira V, Cortinovis D, et al. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. J Exp Clin Cancer Res. 2019;38(1):260.
10. Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271-1277.
11. Liu Y, Dong Y, Jiang QL, et al. Bruton's tyrosine kinase: potential target in human multiple myeloma. Leuk Lymphoma. 2014;55(1):177-181.
12. Zucha MA, Wu AT, Lee WH, et al. Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget. 2015;6(15):13255-13268.
13. Zhang H, Gao B, Shi B. Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma. Dis Markers. 2016;2016:2832980.

Drug Table References:

1. BeiGene USA, Inc. BRUKINSA (zanubrutinib) capsules, for oral use [package insert]. Revised September 2021. www.brukinsa.com/prescribing-information.pdf. Accessed October 20, 2022.
2. AstraZeneca Pharmaceuticals LP. CALQUENCE (acalabrutinib) tablets, for oral use [package insert]. Revised August 2022. www.azpicentral.com/pi.html?product=calquence_tb. Accessed October 20, 2022.
3. Pharmacyclics LLC. IMBRUVICA (ibrutinib) capsules, for oral use; IMBRUVICA (ibrutinib) tablets, for oral use; IMBRUVICA (ibrutinib) oral suspension [package insert]. Revised August 2022. www.imbruvica.com/files/prescribing-information.pdf. Accessed October 20, 2022.
4. Pipeline. Carna Biosciences. Accessed October 21, 2022. www.carnabio.com/english/discovery/pipeline.html.
5. Development Pipeline. BeiGene. Accessed October 21, 2022. www.beigene.com/our-science-and-medicines/pipeline/.
6. Luxeptinib for B-cell Tumors. Aptose Biosciences. Accessed October 21, 2022. www.aptose.com/product-pipeline/luxeptinib-for-b-cell.
7. Our Pipeline. InnoCare. Accessed October 21, 2022. https://cn.innocarepharma.com/en/pipeline/our-pipeline/.
8. Oncology Pipeline. Lilly Oncology. Accessed October 21, 2022. www.lillyloxooncologypipeline.com/molecule/btk-inhibitor.
9. BTK Degraders. Nurix Therapeutics. Accessed October 21, 2022. www.nurixtx.com/pipeline/btk-degraders/